Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to "Strong-Buy" at HC Wainwright

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) was upgraded by analysts at HC Wainwright to a "strong-buy" rating in a research note issued to investors on Tuesday, MarketBeat reports. The brokerage presently has a $9.00 price target on the stock. HC Wainwright also issued estimates for Unicycive Therapeutics' Q4 2026 earnings at $0.47 EPS.

Separately, Guggenheim assumed coverage on shares of Unicycive Therapeutics in a research report on Monday, April 21st. They set a "buy" rating and a $6.00 price target on the stock.

Unicycive Therapeutics Stock Up 3.3%

Shares of NASDAQ:UNCY traded up $0.02 during mid-day trading on Tuesday, reaching $0.61. 639,744 shares of the stock were exchanged, compared to its average volume of 1,493,771. The stock's 50 day simple moving average is $0.59 and its 200-day simple moving average is $0.61. Unicycive Therapeutics has a one year low of $0.20 and a one year high of $0.96. The company has a market cap of $73.69 million, a P/E ratio of -0.63 and a beta of 2.14.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.09. Analysts anticipate that Unicycive Therapeutics will post -0.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp grew its position in shares of Unicycive Therapeutics by 142.4% in the 4th quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after acquiring an additional 34,183 shares during the period. XTX Topco Ltd lifted its stake in Unicycive Therapeutics by 142.2% in the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock valued at $136,000 after purchasing an additional 100,679 shares during the last quarter. Geode Capital Management LLC grew its holdings in Unicycive Therapeutics by 30.3% during the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after purchasing an additional 122,089 shares during the period. Acuta Capital Partners LLC increased its position in Unicycive Therapeutics by 16.4% during the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock worth $1,829,000 after buying an additional 323,801 shares during the last quarter. Finally, Vivo Capital LLC raised its stake in Unicycive Therapeutics by 14.0% in the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock valued at $6,537,000 after buying an additional 1,400,000 shares during the period. 40.42% of the stock is currently owned by institutional investors and hedge funds.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.